This Article Abstract Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Huw Llewelyn, D. Articles by Garcia-Puig, J. Search for Related Content PubMed PubMed Citation Articles by Huw Llewelyn, D. Articles by Garcia-Puig, J. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Blood Pressure Medicines Diabetic Kidney Problems High Blood Pressure Social Bookmarking                         What's this?

How different urinary albumin excretion rates can predict progression to nephropathy and the effect of treatment in hypertensive diabetics

Department of Medicine, Luton and Dunstable Hospital, Lewsey Road, Luton, Bedfordshire, LU1 40Z, UK, HuwLlewelyn@l&d-anglox-nhs.org.uk

Juan Garcia-Puig

Division of Internal Medicine, La Paz Hospital, Universidad Autonoma, Madrid, Spain

Hypothesis The efficacy of a treatment in a clinical trial depends in part on where the cut-off point is placed for the test result used to select patients for the trial, and this applies to irbesartan in the Irbesartan Microalbuminuria II (IRMA II) trial for preventing nephropathy.

Patients and methods Patients in the IRMA II trial were stratified into different pre-treatment albumin excretion rate (AER) ranges to compare the proportion of patients starting in these different ranges (i) that progressed to develop nephropathy within 24 months and (ii) whose AER was over 40 µg/minute at three months.

Results The proportion of patients with pre-treatment AER values between 20 and 40 µg/minute progressing to develop nephropathy was 1.25% in the placebo group and 0.78% in the irbesartan group, while for pre-treatment AER values between 41 and 200 µg/minute, 24.4% and 11.2% develop nephropathy respectively in the placebo and irbesartan groups. In patients with a pre-treatment AER of 20 to 30 µg/minute, 32.5% and 13.6% respectively in the placebo and irbesartan groups had a value exceeding 40 µg/minute at three months.

Conclusions The data demonstrate that irbesartan is effective in reducing the onset of nephropathy within two years when the pre-treatment AER is above 40 µg/minute, but if the AER is below this level it progresses unusually to nephropathy within two years. Irbesartan also slows progression of AER to over 40 µg/minute for patients with pre-treatment AER values at or above 20 µg/minute and these patients should be treated.

Key Words: treatment indication • cut-off points • stratification • albumin excretion rate • microalbuminuria • Type 2 diabetes • irbesartan

References

• Krans HMJ, Porta M., Keen H. Diabetes care and research in Europe: The St Vincent Declaration Action Programme. World Health Organisation, Copenhagen, 1992, pp 29-32.
• Mogensen CE Progression of nephropathy in long-term diabetics with proteinuria and effect of initial anti-hypertensive treatment. Scand J Clin Lab Invest 1976;36:383-8.[Web of Science][Medline] [Order article via Infotrieve]
• Lewis EJ, Hunsicker LG, Bain RP, Rodhe RD The effect of angiotensin converting enzyme inhibition on diabetic nephropathy. N Engl J Med 1993;329:1456-62.[Abstract/Free Full Text]
• Viberti GC, Mogensen CE, Groop LC, Pauls JF Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes and microalbuminuria. JAMA 1994;271:275-7.[Abstract/Free Full Text]
• Melbourne Diabetic Nephropathy Study Group. Comparison between perindopril and nifedipine in hypertensive and normotensive diabetic patients with microalbuminuria. BMJ 1991;302:210-16.[Abstract/Free Full Text]
• The Euclid Study Group. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet 1997;349:1782-92.[Medline] [Order article via Infotrieve]
• Wang PH When should ACE inhibitors be given to normotensive patients with IDDM? Lancet 1997;349:1782.[Medline] [Order article via Infotrieve]
• Williams B. Lisinopril and albumin excretion in diabetics. Lancet 1997;350:663-4.[Medline] [Order article via Infotrieve]
• Jones SL, Viberti GC Microalbuminuria: concepts, definition and monitoring. In: Mogensen CE. (ed.). Microalbuminuria: a marker for organ damage. London: Science Press, 1996;3-9.
• Llewelyn DEH. Assessing the validity of diagnostic tests and clinical decisions. University of London MD thesis, 1988; 197-9.
• Llewelyn H., Hopkins A. Analysing how we reach clinical decisions. London: RCP Publications, 1993; 145-56.
• Parving HH, Lehner H., Brochner-Mortensen J., Gomis R., Andersen S., Arner P.; Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group.The effect of Irbesartan on the development of diabetic nephropathy in patients with Type 2 diabetes. N Engl J Med 2001;345:870-8.[Abstract/Free Full Text]
• Copas JB Plotting p against x. Applied Statistics 1983:32;21-31.

Journal of Renin-Angiotensin-Aldosterone System, Vol. 5, No. 3, 141-145 (2004)
DOI: 10.3317/jraas.2004.031


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This Article Abstract Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Huw Llewelyn, D. Articles by Garcia-Puig, J. Search for Related Content PubMed PubMed Citation Articles by Huw Llewelyn, D. Articles by Garcia-Puig, J. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Blood Pressure Medicines Diabetic Kidney Problems High Blood Pressure Social Bookmarking                         What's this?